whytestocks
5 년 전
News: $VEEV New Veeva OpenData Explorer Provides Online Access to Real-time HCP, HCO, Affiliation, and Compliance Data
Veeva also announces open API making it easier to integrate customer data with third-party applications and services Open approach gives industry flexibility, choice to leverage their customer data without restrictions Life sciences companies want the freedom to use their customer...
Find out more VEEV - New Veeva OpenData Explorer Provides Online Access to Real-time HCP, HCO, Affiliation, and Compliance Data
TFMG
6 년 전
$VEEV TO MUCH RISK INTO EARNINGS, LOOKS LIKE A SHORT
The cloud kings are having real trouble this earnings season, regardless of how good the earnings or outlook is, post earnings selling has hindered any progress. We think NYSE:VEEV is vulnerable as earnings approach , having climbed 80% in 5 months the stock is already overextended, with bearish divergence on the indicators.The stock needs a healthy pullback and it will not have long to wait to get it.
north40000
9 년 전
http://ih.advfn.com/p.php?pid=nmona&article=72242523
"Veeva’s industry cloud solutions gain momentum as companies unify business processes for faster time to market and greater compliance
As life sciences companies continue their transition from legacy on-premises and horizontal cloud software to industry-specific cloud applications, Veeva Systems (NYSE:VEEV) is strengthening its position as a fast-growing, strategic vendor in the industry across its most critical functions. According to Gartner, Veeva’s extensive cloud-based multitenant software solution set across research and development (R&D) and commercial is building the company into a strategic-level vendor for global pharma and biotech clients.1
Increased complexity in life sciences – from global stakeholder ecosystems to regulatory requirements – is driving organizations to streamline operations to be more efficient and agile. This is in an effort to accelerate innovation and get products to market faster and more effectively on a global scale. Organizations are implementing new cloud approaches to improve collaboration and provide smarter ways of working.
As a result, the industry is increasingly relying on Veeva’s applications to streamline their global business operations, with 35 of the top 50 pharmaceutical companies using Veeva Vault to unify their processes and content on a single platform in the areas of commercial, clinical, regulatory, quality and medical.2 Customers are turning to Veeva to help them improve overall business agility, compliance, and risk mitigation.
Over the next five years, Gartner expects migration to multichannel marketing to strengthen and grow within pharma and recognized Veeva as one of only two vendors to offer complete CRM products, support, and services across most of the globe.3 Veeva is in the market share leadership position of the pharma CRM vendor landscape.4
According to IDC Health Insights, Veeva’s continued momentum in the sales and marketing space has strengthened its leadership in the industry.5 “Veeva has leveraged its strong position in the life science CRM space to provide an optimized omni-channel solution for its customers, with access to its cloud-based content management, master data management, and system-wide customer data,” according to the report.
In R&D, Vault Clinical, Vault RIM, and Vault Quality are helping companies streamline their end-to-end clinical trial processes, respond faster to business changes and health authority requests, and integrate their quality processes and content. Within commercial operations, Veeva Commercial Cloud is improving how life sciences companies bring together customer data, compliant content, and multichannel engagement to market and sell more effectively. While Veeva Medical Solutions help organizations discover, target, and engage the right opinion leaders.
“There is a significant shift occurring in the industry to cloud applications that streamline and unify business processes,” said Paul Shawah, vice president of product marketing at Veeva. “Our focus on industry-specific applications is helping our customers transform their R&D, commercial, and medical operations to support faster product launches and quickly adopt new business models. Industry analysts validate that we are gaining momentum as a strategic partner to the industry.”...."
"1 Stephen Davies (Gartner: March 18, 2016), Market Guide for CRM in Pharma and Biotech
2 As of April 30, 2016.
3 Stephen Davies (Gartner: March 18, 2016), Market Guide for CRM in Pharma and Biotech
4 Stephen Davies (Gartner: March 18, 2016), Market Guide for CRM in Pharma and Biotech
5 Alan S. Louie, Ph.D., Michael Townsend, Eric Newmark (IDC Health Insights: June 2016), Business Strategy: Top Software Vendors in the Life Science Industry, 2015"
Alyssa
11 년 전
5 Stocks Set to Soar on Bullish Earnings
Veeva Systems 08/26/14
My first earnings short-squeeze play is cloud-based software solutions provider Veeva Systems (VEEV) , which is set to release numbers on Thursday after the market close. Wall Street analysts, on average, expect Veeva Systems to report revenue of $69.28 million on earnings of 7 cents per share.
The current short interest as a percentage of the float for Veeva Systems is extremely high at 32.4%. That means that out of the 37.24 million shares in the tradable float, 12.09 million shares are sold short by the bears. This is a huge short interest on a stock with a relatively low tradable float. Any bullish earnings news could easily set off a monster short-squeeze that sends the bears scrambling to cover some of their bets.
From a technical perspective, VEEV is currently trending above its 50-day moving average and below its 200-day moving average, which is neutral trendwise. This stock recently spiked sharply higher back above its 50-day moving average with decent upside volume flows. That move has now pushed shares of VEEV within range of triggering a major breakout trade above some key near-term overhead resistance levels post-earnings.
If you're bullish on VEEV, then I would wait until after its report and look for long-biased trades if this stock manages to break out above some near-term overhead resistance levels at $24.80 to $25.08 a share and then above $26.34 a share with high volume. Look for volume on that move that registers near or above its three-month average volume of 998,267 shares. If that breakout hits post-earnings, then VEEV will set up to re-test or possibly take out its next major overhead resistance levels at $29.06 to $34 a share.
http://www.thestreet.com/story/12857487/2/5-stocks-set-to-soar-on-bullish-earnings.html?puc=yahoo&cm_ven=YAHOO
scanx
11 년 전
Why. #1 95% of revenue tied to Salesforce.com platform Force.com. Their contract expires in 2015. Salesforce is making moves in life science space above and beyond Veev. #2 Because of this dependence their IP is materially tied up with Force.com capability, functionality, etc--it is not easy to port the Veeva CRM to another open source platform for example if not practically impossible #3 CRM space getting fairly saturated--they will continue to grow but not at the pace they have fairly soon; #4 Veeva Vault is a key market segment to expand rapidly to keep justifying multiples and extremely high valuation--problems with Vault include A) regulated content management highly slow moving space--sales cycles long and complex even for a few hundred thousand dollar deal B) space is very competitive from large players like EMC (Documentum); Microsoft (SharePoint); Oracle (various content management capabilities); IBM (Websphere,FileNet, etc), Open Text (Livelink, et al), etc. to niche traditional players such as Qumas, CSC< MasterControl, NextDocs, Pilgrim, etc. to new horizontal open source/cloud upstarts that will move into this space including Box, DropBox and multiple others. In summary regulated content management space VERY competitive; conservative industry; long sales cycles; highly controlled processes, etc...Anything but a fast moving; high growth market. Moreover in life science space Documentum maintains near 100% penetration of market (it is the regulated ECM standard) and most compliance systems have eSignatures stored in these system. Even if Veeva gives away free many companies won't move--too much risk; too much compliance anxiety. A few will move to Veev and Veev will continue to expand in this space but the growth won't be at the rate over the next 24 months that the market expects #5 data management and other solutions could be compelling since they are accumulating a lot of information but they will from an architectural standpoint have to move OFF of Force to breakout here. Overall fantastic execution by leadership. Kudos to them but it is inevitable that sooner rather than later this company will move down to 4X to 5X their revenues.
56Chevy
11 년 전
Veeva Announces Fiscal 2014 Third Quarter Results
Date : 12/05/2013 @ 4:02PM
Source : Business Wire
Stock : VEEVA SYSTEMS INC (VEEV)
Quote : $40.98 0.84 (2.09%) @ 8:00PM
Fiscal 2014 Third Quarter Results:
•Revenues: Total revenues for the third quarter were $55.0 million, up from $35.8 million one year ago, an increase of 54% year-over-year. Subscription services revenues were $38.9 million, up from $20.0 million one year ago, an increase of 95% year-over-year.
[....]
Financial Outlook:
Veeva is providing guidance for the fourth quarter of fiscal 2014 as follows:
• Total revenues between $57 and $58 million, an increase of 43% to 46% on a year-over-year basis. This implies full fiscal year revenues of approximately $204 to $205 million representing annual growth of 58% to 59%.
[....]
http://ih.advfn.com/p.php?pid=nmona&article=60289751
Hot Features
프리미엄
브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
OptimusPrime555
3 년 전
T695
4 년 전
TheFinalCD
8 년 전
Panzer
8 년 전
stocktrademan
10 년 전
